PORTLAND, Maine, May 14, 2020 /PRNewswire/ -- ImmuCell
Corporation (NASDAQ: ICCC) a growing animal health
company that develops, manufactures and markets
scientifically-proven and practical products that improve the
health and productivity of dairy and beef calves,
today announced it will participate in a virtual
presentation and fireside chat at the May
2020 Lytham Partners Virtual Investor Conference on
Wednesday, May 20, 2020 at
11:00am ET (8:00am PT).
A webcast of the presentation will be posted under the investor
relations section of the ImmuCell website at
www.immucell.com or can be accessed at
https://www.webcaster4.com/Webcast/Page/1214/34875. A replay of the
presentation will be available following the event.
Management will also be participating in virtual one-on-one
meetings on May 21, 2020. To arrange
a meeting, please contact Joe Diaz
of Lytham Partners at diaz@lythampartners.com or visit
www.lythampartners.com/virtual.
About ImmuCell:
ImmuCell Corporation's (Nasdaq:
ICCC) purpose is to create scientifically-proven and practical
products that improve the health and productivity of dairy and beef
calves. ImmuCell manufactures and markets First
Defense®, providing Immediate Immunity™ to
newborn dairy and beef calves, and is in the late stages of
developing Re-Tain™, a novel treatment for subclinical
mastitis without a milk discard requirement that provides an
alternative to traditional antibiotics. Press releases and other
information about the Company are available at:
http://www.immucell.com.
Cautionary Note Regarding Forward-Looking Statements
(Safe Harbor Statement):
This Press
Release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating
to: our plans and strategies for our business; projections of
future financial or operational performance; the timing and outcome
of pending or anticipated applications for regulatory approvals;
factors that may affect the dairy and beef industries and future
demand for our products; the extent, nature and duration of the
COVID-19 pandemic and its consequences, and their direct and
indirect impacts on the Company's production activities, operating
results and financial condition and on the customers and markets
the Company serves; the scope and timing of ongoing and future
product development work and commercialization of our products;
future costs of product development efforts; the estimated
prevalence rate of subclinical mastitis and dairy producers' level
of interest in treating subclinical mastitis given current economic
and market conditions; the expected efficacy of new products;
estimates about the market size for our products; future market
share of and revenue generated by current products and products
still in development; our ability to increase production output and
reduce costs of goods sold associated with our new product,
Tri-Shield First Defense®; the future adequacy of our own
manufacturing facilities or those of third parties with which we
have contractual relationships to meet demand for our products on a
timely basis; the anticipated costs of (or time to complete)
planned expansions of our manufacturing facilities and the adequacy
of our funds available for these projects; the continuing
availability to us on reasonable terms of third-party providers of
critical products or services; the robustness of our manufacturing
processes and related technical issues; estimates about our
production capacity, efficiency and yield; the future adequacy of
our working capital and the availability and cost of third-party
financing; future regulatory requirements relating to our products;
future expense ratios and margins; future compliance with bank debt
covenants; costs associated with sustaining compliance with current
Good Manufacturing Practice (cGMP) regulations in our current
operations and attaining such compliance for the facility to
produce the Nisin Drug Substance; implementation of international
trade tariffs that could reduce the export of dairy products, which
could in turn weaken the price received by our customers for their
products; our effectiveness in competing against competitors within
both our existing and our anticipated product markets; the
cost-effectiveness of additional sales and marketing expenditures
and resources; anticipated changes in our manufacturing
capabilities and efficiencies; the value of our net deferred tax
assets; projections about depreciation expense and its impact on
income for book and tax return purposes; anticipated market
conditions; and any other statements that are not historical facts.
Forward-looking statements can be identified by the use of words
such as "expects", "may", "anticipates", "aims", "intends",
"would", "could", "should", "will", "plans", "believes",
"estimates", "targets", "projects", "forecasts", "seeks" and
similar words and expressions. In addition, there can be no
assurance that future developments affecting us will be those that
we anticipate. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties
relating to difficulties or delays in development, testing,
regulatory approval, production and marketing of our products
(including the First Defense® product line and
Re-Tain™), competition within our anticipated product
markets, customer acceptance of our new and existing products,
product performance, alignment between our manufacturing resources
and product demand, our reliance upon third parties for financial
support, products and services, changes in laws and regulations,
decision making and delays by regulatory authorities, currency
values and fluctuations and other risks detailed from time to time
in filings we make with the SEC, including our Quarterly Reports on
Form 10-Q, our Annual Reports on Form 10-K and our Current Reports
on Form 8-K. Such statements involve risks and uncertainties and
are based on our current expectations, but actual results may
differ materially due to various factors, including the risk
factors summarized above.
Contacts:
|
Michael F. Brigham,
President and CEO
ImmuCell
Corporation
(207)
878-2770
Joe Diaz, Robert Blum
and Joe Dorame
Lytham Partners,
LLC
(602)
889-9700
iccc@lythampartners.com
|
View original
content:http://www.prnewswire.com/news-releases/immucell-corporation-to-present-at-lytham-partners-virtual-investor-conference-301059637.html
SOURCE ImmuCell Corporation